OGEN vs ONCO

Oragenics Inc. vs Onconetix, Inc. — Valuation Comparison 2026

OGEN

Biotechnology
Oragenics Inc.
Quality
4.5
out of 10
Value Trap
12
SAFE
Price
$0.60
Last close
Models
6/13
Active
VS

ONCO

Biotechnology
Onconetix, Inc.
Quality
4.5
out of 10
Value Trap
49
WARN
Price
$1.17
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType OGEN Fair ValueOGEN Upside ONCO Fair ValueONCO Upside
Bayesian DCF Intrinsic $0.90 +49.9% $1.89 +61.5%
Earnings Power Value Intrinsic $1.51 +138.5%
EROIC Spread Intrinsic $•••.•• ••.•% $•••.•• ••.•%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.14 -76.9%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for OGEN vs ONCO — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OGEN vs ONCO — Which Stock Is More Undervalued?

ONCO scores higher with a 4.5/10 quality rating vs OGEN's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oragenics Inc. (OGEN) and Onconetix, Inc. (ONCO) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OGEN currently trades at $0.60 with a QOC of 4.5/10, while ONCO trades at $1.17 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).